In this study, we applied the advanced DIA-based proteomic workflow not only to canonical AD patients, defined by decreased amyloid beta 1 to 42 (Aβ42) and increased total tau in the CSF, but also to a distinct subgroup of AD patients, who were cognitively indistinguishable and had similarly reduced Aβ42 levels, but showed normal CSF tau levels (Aβ+/tau+ and Aβ+/tau- AD patients). This evidence concerns the gene MAPT and Alzheimer disease.